Bitwise to Buy HYPE Token Using Hyperliquid ETF Fees

Bitwise will add the HYPE token to its corporate balance sheet by buying tokens with fee income from its Hyperliquid ETF, not with investor assets held in the fund.

Bitwise announced plans to add the HYPE token to its corporate balance sheet using fee revenue from its Hyperliquid ETF. The company said the purchases will be funded with management fees it receives, not with assets held inside the ETF.

Bitwise is an asset manager that operates exchange-traded funds, including the Hyperliquid ETF. Management and operating charges collected by the fund become cash revenue for the firm after they are paid to the manager.

Under the plan, Bitwise will convert some of the cash fees it receives from managing the Hyperliquid ETF into HYPE tokens and record those tokens as part of the company’s corporate treasury. The company described the ETF fees as the funding source and stated the ETF’s portfolio will remain separate from corporate holdings.

The announcement did not include a timetable, the share of fee revenue to be used for purchases, or the expected size of the HYPE position. The company said token holdings will be reflected on its financial statements according to applicable accounting standards.

Tokens on a corporate balance sheet are subject to valuation and reporting rules and may show market-price volatility. Bitwise indicated it will disclose the HYPE holdings in corporate filings and investor communications as required by regulation.

Bitwise provided no additional operational details about how it will use HYPE, including any governance rights or strategic plans for the tokens.

The content on The Coinomist is for informational purposes only and should not be interpreted as financial advice. While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, or reliability of any content. Neither we accept liability for any errors or omissions in the information provided or for any financial losses incurred as a result of relying on this information. Actions based on this content are at your own risk. Always do your own research and consult a professional. See our Terms, Privacy Policy, and Disclaimers for more details.

Articles by this author